Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–12 of 12 results
Advanced filters: Author: Leila Akkari Clear advanced filters

  • In this Viewpoint, Nature Reviews Immunology invites eight experts in the field to share their thoughts on the key questions and challenges in MDSC research.

    • Leila Akkari
    • Ido Amit
    • Suzanne Ostrand-Rosenberg
    Reviews
    Nature Reviews Immunology
    Volume: 24, P: 850-857

  • Beneficial effects of fasting combined with endocrine therapy for oestrogen receptor-α-expressing breast cancers can be recapitulated using exogenous glucocorticoid receptor ligands instead of fasting to reduce harmful effects.

    • Nuno Padrão
    • Tesa M. Severson
    • Wilbert Zwart
    ResearchOpen Access
    Nature
    Volume: 649, P: 1013-1021

  • Twelve early-career investigators share their thoughts on the challenges faced by their teams and communities during the past year, and look ahead to new opportunities for 2022.

    • Leila Akkari
    • Stacey D. Finley
    • Meng Michelle Xu
    Reviews
    Nature Cancer
    Volume: 2, P: 1278-1283

  • Distinct genetic mutations can shape the tumor immune microenvironment. Here the authors generate preclinical mouse models of hepatocellular carcinoma bearing clinically-relevant oncogenic driver combinations, identifying myeloid cell-centric exploitable therapeutic vulnerabilities.

    • Christel F. A. Ramirez
    • Daniel Taranto
    • Leila Akkari
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-24

  • Metabolic disorders, such as obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes, are increasingly recognized as significant contributors to cancer development. Here, Taranto, Kloosterman and Akkari explore the influence of metabolic disorders on tumour progression through the metabolic interactions of macrophages and T cells to alter immune function and cancer outcomes.

    • Daniel Taranto
    • Daan J. Kloosterman
    • Leila Akkari
    Reviews
    Nature Reviews Cancer
    Volume: 24, P: 744-767

  • The authors provide preclinical testing of a CSFR-1 inhibitor in proneural glioma models. The compound targets macrophages in the tumor microenvironment rather than tumor cells themselves and is shown to portend considerable antitumor effects. Its activity relies on re-education of tumor-associated macrophages without affecting their survival, reverting their tumor-promoting phenotype. Moreover, gene signatures capturing the tumorigenic features of macrophages can predict survival in human patients with glioma, underscoring the potential relevance of this strategy as a glioma therapy.

    • Stephanie M Pyonteck
    • Leila Akkari
    • Johanna A Joyce
    Research
    Nature Medicine
    Volume: 19, P: 1264-1272

  • EGFR inhibition and lenvatinib treatment of liver cancer cells in vitro and in in vivo mouse models has potent anti-proliferative effects, and lenvatinib plus gefitinib treatment of 12 patients with advanced liver cancer resulted in meaningful clinical responses.

    • Haojie Jin
    • Yaoping Shi
    • René Bernards
    Research
    Nature
    Volume: 595, P: 730-734

  • Imaging mass cytometry of human brain tumours provides spatial information that, combined with existing transcriptomic data, reveals the existence of a cellular neighbourhood containing a rare macrophage population associated with prolonged survival.

    • Elham Karimi
    • Miranda W. Yu
    • Logan A. Walsh
    ResearchOpen Access
    Nature
    Volume: 614, P: 555-563

  • CDC7 inhibition selectively induces senescence in hepatocellular carcinoma cells with TP53 mutations, which enables the selective apoptotic cell death of these senescent cells using inhibitors of mTOR signalling.

    • Cun Wang
    • Serena Vegna
    • René Bernards
    Research
    Nature
    Volume: 574, P: 268-272

  • The tumor microenvironment is recognized as a critical regulator of cancer progression, and multiple roles are also emerging for the microenvironment in modulating response to therapeutic intervention. A recent study by Wang and colleagues identified IFN-γ as a central effector of CD8+ T cell-mediated regulation of glutathione and cysteine metabolism in fibroblasts, which consequently abrogates stromal-induced resistance through modulation of cisplatin intracellular content in ovarian cancer cells.

    • Leila Akkari
    • Johanna A Joyce
    Research Highlights
    Cell Research
    Volume: 26, P: 867-868